Boston Scientific Corporation
BSX has signed a definitive agreement to acquire BridgePoint Medical,
Inc., a privately held company based in Minneapolis, Minnesota. BridgePoint
Medical has developed a proprietary, catheter-based system to treat coronary
chronic total occlusions (CTOs). The transaction is expected to close in the
fourth quarter of 2012 subject to customary closing conditions.
The BridgePoint Medical CTO system is comprised of the CrossBoss^™ CTO
Crossing Catheter and the Stingray^® CTO Re-Entry System, and is designed to
navigate highly diseased (occluded) coronary arteries as a means of blood flow
restoration. The system has received both U.S. Food and Drug Administration
clearance and CE Mark, and is currently the only crossing and re-entry system
cleared in the U.S. for use in coronary CTOs.
"The BridgePoint Medical CTO system is a compelling addition to our
industry-leading suite of cardiology products," said Kevin Ballinger,
president of the Interventional Cardiology Division at Boston Scientific.
"This acquisition strengthens our portfolio and demonstrates the Boston
Scientific commitment to continued leadership in interventional cardiology."
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in